Items where Author is "Hoener, M. C."

Yes

Harmeier, A. and Obermueller, S. and Meyer, C. A. and Revel, F. G. and Buchy, D. and Chaboz, S. and Dernick, G. and Wettstein, J. G. and Iglesias, A. and Rolink, A. and Bettler, B. and Hoener, M. C.. (2015) Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers. European Neuropsychopharmacology, 25 (11). pp. 2049-2061.

Simmler, L. D. and Rickli, A. and Hoener, M. C. and Liechti, M. E.. (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology, Vol. 79. pp. 152-160.

Hysek, C. M. and Simmler, L. D. and Nicola, V. G. and Vischer, N. and Donzelli, M. and Krahenbuhl, S. and Grouzmann, E. and Huwyler, J. and Hoener, M. C. and Liechti, M. E.. (2012) Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE, Vol. 7, H. 5 , e36476.

Hysek, C. M. and Brugger, R. and Simmler, L. D. and Bruggisser, M. and Donzelli, M. and Grouzmann, E. and Hoener, M. C. and Liechti, M. E.. (2012) Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. Journal of pharmacology and experimental therapeutics, Vol. 340, H. 2. pp. 286-294.

Simmler, L. D. and Buser, T. A. and Donzelli, M. and Schramm, Y. and Dieu, L. H. and Huwyler, J. and Chaboz, S. and Hoener, M. C. and Liechti, M. E.. (2012) Pharmacological characterization of designer cathinones in vitro. British journal of pharmacology, Vol. 168, no. 2. pp. 458-470.

Revel, F. G. and Moreau, J. L. and Gainetdinov, R. R. and Bradaia, A. and Sotnikova, T. D. and Mory, R. and Durkin, S. and Zbinden, K. G. and Norcross, R. and Meyer, C. A. and Metzler, V. and Chaboz, S. and Ozmen, L. and Trube, G. and Pouzet, B. and Bettler, B. and Caron, M. G. and Wettstein, J. G. and Hoener, M. C.. (2011) TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, H. 20. pp. 8485-8490.

Hysek, C. M. and Simmler, L. D. and Ineichen, M. and Grouzmann, E. and Hoener, M. C. and Brenneisen, R. and Huwyler, J. and Liechti, M. E.. (2011) The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA ("Ecstasy") in Humans. Clinical pharmacology and therapeutics, 90 (2). pp. 246-255.